Number and impact of acute and chronic cases of hepatitis B virus, by scenario
| Scenario | No. of cases of acute HBV | Cumulative burden 2020–2050 | ||||
|---|---|---|---|---|---|---|
| No. of cases of chronic HBV | Cumulative direct costs, millions of Can$ | Cumulative costs averted, millions of Can$ | DALYs averted | Cost per DALY averted, Can$ | ||
| 1. Base(current adolescent schedule) | 1500 | 520 | 3333 | – | – | – |
| 2. Three individual doses (0, 1 and 6 mo) | 940 | 360 | 3424 | 91 | 54 | 1 675 000 |
| 3. Two individual, 1 combined (0, 1 and 6 mo) | 940 | 360 | 3370 | 62 | 54 | 671 000 |
| 4. One individual, 2 combined (0, 2 and 6 mo) | 940 | 360 | 3339 | 6 | 54 | 103 000 |
| 5. Three combined (2, 4 and 6 mo) | 950 | 370 | 3310 | −23 | 54 | −428 000 |
Note: DALY = disability-adjusted life year, HBV = hepatitis B virus.